- Home
- SJT vs FENC Comparison
SJT vs FENC Comparison
Compare SJT & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SJT
- FENC
- Stock Information
- Founded
- SJT 1980
- FENC 1996
- Country
- SJT United States
- FENC United States
- Employees
- SJT N/A
- FENC N/A
- Industry
- SJT Oil & Gas Production
- FENC Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SJT Energy
- FENC Health Care
- Exchange
- SJT Nasdaq
- FENC Nasdaq
- Market Cap
- SJT 212.1M
- FENC 156.9M
- IPO Year
- SJT N/A
- FENC 2001
- Fundamental
- Price
- SJT $4.38
- FENC $6.00
- Analyst Decision
- SJT
- FENC Strong Buy
- Analyst Count
- SJT 0
- FENC 2
- Target Price
- SJT N/A
- FENC $14.00
- AVG Volume (30 Days)
- SJT 302.4K
- FENC 69.5K
- Earning Date
- SJT 11-14-2024
- FENC 03-20-2025
- Dividend Yield
- SJT 2.53%
- FENC N/A
- EPS Growth
- SJT N/A
- FENC N/A
- EPS
- SJT 0.19
- FENC N/A
- Revenue
- SJT $11,031,594.00
- FENC $49,348,000.00
- Revenue This Year
- SJT N/A
- FENC $170.43
- Revenue Next Year
- SJT N/A
- FENC $6.70
- P/E Ratio
- SJT $23.65
- FENC N/A
- Revenue Growth
- SJT N/A
- FENC 278.09
- 52 Week Low
- SJT $3.21
- FENC $3.96
- 52 Week High
- SJT $5.81
- FENC $11.49
- Technical
- Relative Strength Index (RSI)
- SJT 54.89
- FENC 50.02
- Support Level
- SJT $4.21
- FENC $5.47
- Resistance Level
- SJT $4.81
- FENC $5.99
- Average True Range (ATR)
- SJT 0.23
- FENC 0.27
- MACD
- SJT 0.02
- FENC -0.06
- Stochastic Oscillator
- SJT 55.21
- FENC 35.14
About SJT San Juan Basin Royalty Trust
San Juan Basin Royalty Trust is an energy sector royalty trust in the United States. It owns approximately 75% net profit interest in a large number of natural gas properties in the San Juan Basin of New Mexico. About 98% of the royalties San Juan collects come from natural gas, with the balance coming from oil.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.